Every month ECDC provides detailed epidemiological overview of the worldwide transmission of chikungunya in its weekly threat report (Communicable Diseases Threat Report).
In this episode we take a closer look at the data collection for respiratory viruses and why we should take this more seriously than just a cough or a sneeze.
ECDC and World Health Organization (WHO) Regional Office for Europe have jointly developed the European Respiratory Virus Surveillance Summary (ERVISS), an interactive surveillance data dashboard for influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that also features a weekly epidemiological summary.
As autumn moves to winter, the WHO/Europe, EC and ECDC are issuing a clear, urgent message: people who remain unprotected against both COVID-19 and seasonal influenza – especially the most vulnerable and at-risk – should take up any offer for vaccination to prevent or mitigate the impact of these co-circulating respiratory infections.
In a technical report published today, ECDC, proposes a targeted testing approach in areas with ongoing avian influenza outbreaks in poultry and detections in wild birds and other animals, focusing on severe respiratory or unexplained neurological disease.
The mosquito species Aedes albopictus, a known vector of chikungunya and dengue viruses, is establishing itself further northwards and westwards in Europe, according to the latest data.
The situation regarding avian influenza continues to evolve in Europe and globally, with reports of new outbreaks in birds and occasional infections in mammals. Sporadic human infections have been reported in countries outside the EU, while the risk to the public in the EU remains low.
In February 2023, Cambodia reported a family cluster in Sithor Kandal district, Prey Veng province, with two people (a girl and her father) infected with avian influenza A(H5N1) virus.